KR102224110B1 - Composition for reducing the skin pore containing a substance related to regulation of ABH antigen expression - Google Patents

Abstract

The present invention relates to a composition for shrinking pores, and more specifically, a composition capable of providing an antioxidant effect by controlling the expression of ABH antigen, thereby preventing the pores from widening, and also preventing the generation of skin irritation. It is about.

Description

Composition for reducing the skin pore containing a substance related to regulation of ABH antigen expression

The present invention relates to a composition for shrinking pores, and more specifically, a composition capable of providing an antioxidant effect by controlling the expression of ABH antigen, thereby preventing the pores from widening, and also preventing the generation of skin irritation. It is about.

Blood type antigen refers to a structure with specific antigenicity found in glycoproteins or glycolipids on the surface of red blood cells in blood. Representatively, there are ABO type blood type antigen (ABH antigen), Lewis type blood type antigen, and the like, and the blood type is determined according to the structure of the glycosylation end group of a specific structure. ABO-type blood-type antigen and Lewis-type blood-type antigen are not only expressed in red blood cells, but are found in various parts of the human body. It is known and is expressed in the granular layer of the epidermis in the skin.

Since the expression of the ABO type blood type antigen in the granular layer of the epidermis appears in the outermost layer of the skin in an anatomical position, it is closely related to skin-related diseases, particularly inflammatory diseases.

As described above, ABO-type blood type antigen is a very important antigen that is the main cause of rejection of blood transfusion and organ transplantation, but since its discovery in 1900, little has been studied on physiological functions other than rejection.

Accordingly, the present inventors confirmed that the regulation of ABH antigen expression is related to antioxidant efficacy, pore enlargement prevention, and skin aging prevention, and completed the present invention.

Accordingly, it is an object of the present invention to provide a composition effective in preventing pore shrinkage and pore expansion or preventing skin aging by controlling the expression of ABH antigen.

In order to achieve the above object, the present invention provides a composition for shrinking pores comprising, as an active ingredient, a substance that regulates the expression of the ABH antigen.

In addition, the present invention provides a composition for preventing pore expansion comprising a substance that regulates the expression of the ABH antigen as an active ingredient.

In addition, the present invention provides a composition for preventing skin aging, comprising as an active ingredient a substance that regulates the expression of the ABH antigen.

The composition of the present invention contains a substance that regulates the expression of ABH antigen as an active ingredient, reduces pores by removing active oxygen and promoting collagen synthesis, and has an excellent effect of preventing the generation of skin irritation due to its excellent antioxidant power. .

1 shows the structure of the ABH antigen and Lewis type blood type antigen.
Figure 2 shows that the expression of the B antigen in the HaCaT cell line is increased by substances that regulate the expression of the ABH antigen.

The present invention relates to a composition containing as an active ingredient a substance that regulates the expression of the ABH antigen.

In particular, the composition of the present invention exhibits an effect of reducing pores, preventing pore expansion, or preventing skin aging by controlling the expression of the ABH antigen.

In the present specification, "ABH antigen" refers to a structure having a specific antigenicity expressed in glycoproteins or glycolipids on the surface of red blood cells of blood, and representatively, ABH antigens are ABH antigens represented in FIG. 1, ABH antigens such as Lewis type blood type antigens, etc. It is used in the sense of including all the aggregates of analogues. The ABH antigen analog is a substance to which monosaccharides, amino acids, etc. are additionally bound, and refers to substances that have the same function as the original function of the ABH antigen. Figure 1 shows the structure of the ABH antigen and Lewis type blood type antigen.

In the present specification, "active ingredient" refers to an ingredient that exhibits a desired activity by itself or can exhibit activity together with a carrier that does not have its own activity.

In the composition of the present invention, the substance that modulates the expression of the ABH antigen includes a substance that increases the expression of the ABH antigen. The increase in the expression of the ABH antigen may be specifically caused by the increase in the expression of the B antigen in the HaCaT cell line.

In the composition of the present invention, the substance that regulates the expression of the ABH antigen is 1,3-dicaffeoylquinic acid (Formula 1), 1,5-dicafeoylquinic acid (1 ,5-dicafeoylquinic acid) (Chemical Formula 2) and amentoflavone (Chemical Formula 3) at least one compound selected from the group consisting of, a derivative thereof, or a pharmaceutically acceptable salt thereof.

In the present specification, "derivative" refers to all compounds that are changed with other substituents at the position where the compound can be substituted, and there is no limitation on the kind of such a substituent.

As used herein, "pharmaceutically acceptable" means approval of the government or equivalent regulatory body for use in animals, more specifically in humans, by avoiding significant toxic effects when used in conventional medicinal dosages. It means available or approved, listed in the pharmacopoeia, or recognized as other general pharmacopoeia.

In the present specification, "pharmaceutically acceptable salt" refers to a salt according to one aspect of the present invention that is pharmaceutically acceptable and possesses a desirable pharmacological activity of a parent compound. The salt is (1) formed of an inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, or the like; Or acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl) Benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-Toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo [2,2,2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tert -Acid addition salts formed from organic acids such as butyl acetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid; Or (2) a salt formed when an acidic proton present in the parent compound is substituted.

The composition of the present invention may contain a substance that modulates the expression of the ABH antigen in an amount of 0.001% to 20% by weight based on the total weight of the composition.

When the substance that regulates the expression of the ABH antigen is used within the above range, it is not only suitable for exhibiting the intended pore reduction, pore expansion prevention, or skin irritation generation protective effect of the present invention, but also satisfies both the stability and safety of the composition. , It is useful in terms of cost-effectiveness. In view of the above, the composition of the present invention contains a substance that controls the expression of the ABH antigen, based on the total weight of the composition, from 0.005% to 19.5% by weight, from 0.01% to 19% by weight, from 0.015% to 18.5% by weight, and 0.02. Included in an amount of from weight% to 18% by weight, from 0.025% to 17.5% by weight, from 0.03% to 17% by weight, from 0.035% to 16.5% by weight, from 0.04% to 16% by weight, or from 0.045% to 15.5% by weight can do.

The composition of the present invention can reduce pores by promoting active oxygen removal and collagen synthesis, and can prevent pore enlargement or skin aging. Also, due to its excellent antioxidant power, the composition of the present invention inhibits the production of reactive oxygen species, thereby inhibiting skin inflammation, thereby irritating the skin You can defend against the creation of.

In the composition of one aspect of the present invention, the composition may be a cosmetic composition.

The formulation of the cosmetic composition is not particularly limited, and may be appropriately selected depending on the intended purpose. For example, softening lotion (skin lotion and milk lotion), nutritional lotion, essence, nutrition cream, massage cream, pack, gel, essence, eye cream, eye essence, cleansing cream, cleansing foam, cleansing water, pack, powder, It may be prepared in one or more formulations selected from the group consisting of body lotion, body cream, body oil, and body essence, but is not limited thereto. In addition, the cosmetic composition may include use as an external preparation for skin in the form of an ointment, patch, or the like.

The cosmetic composition according to the present invention can be provided in any formulation suitable for topical application. For example, it may be provided in the form of a solution, an emulsion obtained by dispersing an oil phase in an aqueous phase, an emulsion obtained by dispersing an aqueous phase in an oil phase, a suspension, a solid, a gel, a powder, a paste, a foam, or an aerosol composition. Compositions of such formulations can be prepared according to conventional methods in the art.

The cosmetic composition according to the present invention may include other ingredients that can give a synergistic effect to the main effect, preferably within a range that does not impair the main effect in addition to the above-described substances. In addition, the cosmetic composition according to the present invention may further include a moisturizing agent, an emollient agent, an ultraviolet absorber, a preservative, a disinfectant, an antioxidant, a pH adjuster, an organic and inorganic pigment, a fragrance, a cooling agent or a limiting agent. The blending amount of the ingredients can be easily selected by a person skilled in the art within a range that does not impair the object and effect of the present invention, and the blending amount is 0.01 to 5% by weight, specifically 0.01 to 3% by weight, based on the total weight of the composition. Can be

In the composition of one aspect of the present invention, the composition may be a pharmaceutical composition.

The formulation of the pharmaceutical composition according to the present invention may be a solution, a suspension, an emulsion, a gel, a drop, a suppository, a patch, or a spray, but is not limited thereto. The formulation can be easily prepared according to conventional methods in the art, and excipients, hydrating agents, emulsification accelerators, suspending agents, salts or buffers for controlling the osmotic pressure, coloring agents, spices, stabilizers, preservatives, preservatives or other compatible Adjuvants can be used in moderation.

The active ingredient of the pharmaceutical composition of the present invention will vary depending on the age, sex, weight, pathological condition and severity of the subject to be administered, the route of administration, or the judgment of the prescriber. Determination of the application amount based on these factors is within the level of those skilled in the art, and its daily dose is, for example, from 0.000025 mg/g/day to 0.025 mg/g/day, more specifically from 0.00025 mg/g/day to 0.01 mg/day. It may be g/day, but is not limited thereto.

The pharmaceutical composition of the present invention may be administered orally or transdermally, but is not limited thereto.

In addition, the present invention provides a method for screening a substance having pore-reducing or pore-enlarging inhibitory activity and/or skin aging inhibitory activity, the method comprising:

1) checking the expression level of the ABH antigen expressed in the test skin cell;

2) treating the test skin cells with a candidate substance;

3) checking the expression level of the ABH antigen in the cells of step 2); And

4) comparing the results of steps 1) and 3) to determine whether or not it is a substance that increases the expression of the ABH antigen;

Includes.

In the above method, it may be determined that a substance that increases the expression of the ABH antigen is effective in reducing pores or preventing pore expansion, or preventing skin aging.

In the present invention, the substance that regulates the expression of the ABH antigen is 1,3-dicafeoylquinic acid, 1,5-dicafeoylquinic acid. And at least one compound selected from the group consisting of amentoflavone, a derivative thereof, or a pharmaceutically acceptable salt thereof.

Hereinafter, the present invention will be described in more detail through examples. These examples are for illustrative purposes only, and it will be apparent to those of ordinary skill in the art that the scope of the present invention is not construed as being limited by these examples.

[Test Example 1] Effect of increasing the expression of B antigen in HaCaT cell line

The effects of various types of compounds on the expression of ABH antigen were tested. To this end, HaCaT cells (provided by Prof. Dr. NE Fusenig, DKFZ Heidelberg, Germany) were incubated in a 35 mm dish with 10% FBS-DMEM for 24 hours, and then incubated with 0% FBS-DMEM for 24 hours to starvation. Made with While changing the medium with 0% FBS-DMEM again, various kinds of compounds as test substances were treated on HaCaT cells at a concentration of 2 μg/ml, respectively, and cultured for 48 hours. At this time, for comparison, the control group was treated with DMSO at the same concentration as the sample. Among the test substances, three substances that significantly increase the expression of the ABH antigen, namely 1,3-dicaffeoylquinic acid, 1,5-dicafeoylquinic acid (1,5- dicafeoylquinic acid) and amentoflavone were identified (data not shown). In the case of treatment with these three compounds, proteins were extracted from the cells and the cell lysate was loaded in the same amount, Expression was examined. As a control, alpha-tubulin protein was used. The measurement results are shown in FIG. 2.

Referring to FIG. 2, it can be seen that 1,3-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, and amentoflavone all have the effect of increasing the expression of type B antigen in HaCaT cells.

[Test Example 2] Effect of inhibiting production of reactive oxygen species

The keratinocytes (keratinocyte) isolated from the skin tissue of the person into a 5 × 10 ⁴ are in each well of a 24 well (well) cell culture plate was attached for 24 hours. After removing the culture solution, 100 µl of phosphate buffered saline (PBS) was added to each well. After irradiating the keratinocytes with UV rays of 30 mJ/cm 2 using an ultraviolet B (UV B) lamp (Model: F15T8, UV B 15W, Sankyo Dennki, Japan), PBS was removed, and keratinocyte culture solution 200 was applied to each well. Μl was added. Here, as test substances, 1,3-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, and amentoflavone were treated with 2 μg/ml, respectively, and reactive oxygen species increased by UV stimulation at a certain time period. , ROS) was quantified. At this time, for comparison, the amount of reactive oxygen species was also measured for those that were not treated with the test substance (no treatment) and were not stimulated with ultraviolet rays, and those that were stimulated with ultraviolet rays without treatment with the test substance. The amount of ROS was quantified by referring to Tan's method of measuring the fluorescence of DCF-DA (dichlorofluorescin diacetate) oxidized by ROS (Tan et al., 1998, J. Cell Biol. Vol. 141, pp1423-1432), The ratio of the control group to ROS is shown in Table 1 below.

Time elapsed after UVB 30mJ/cm ^{2 irradiation} 0 hours 2 hours 3 hours No treatment 100 244 287 UVB + no treatment 100 325 381 UVB+1,3-DicafeOylquinic Acid 100 277 319 UVB+1,5-dicafe oil quinic acid 100 280 315 UVB + Amentoflavone 100 288 320

From the results shown in Table 1 above, the 1,3-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, and amentoflavones of the present invention effectively inhibit the production of ROS, which is known to cause skin cell damage by ultraviolet rays. It can be confirmed that it inhibits, and thus, it can be seen that these substances have excellent antioxidant efficacy.

Therefore, 1,3-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, and amentoflavone contained in the composition of the present invention can prevent widening of pores by inhibiting oxidation and preventing aging, In addition, it can be seen that the production of skin irritation can be prevented.

[Test Example 3] Promoting collagen biosynthesis

The effect of promoting collagen biosynthesis of 1,3-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid and amentoflavone used in the present invention was measured by comparing with TGF-beta.

^{First, fibroblasts were seeded 10 5} in each well of a 24-well plate and cultured until about 90% growth. After incubating this in a serum-free DMEM medium for 24 hours, 1,3-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, amentoflavone and TGF-beta were treated with 2 μg/ml, respectively, and Incubated in a _{CO 2} incubator for 24 hours. The supernatant was removed and the increase or decrease of procollagen was examined using a procollagen type (I) ELISA kit (procollagen type (I)). The results are shown in Table 2, and the synthesis ability of collagen was compared with the untreated group as 100.

division Collagen synthesis ability (%) Untreated group 100 TNF-beta 183.5±13.1 1,3-dicafeoylquinic acid 142.1±13.1 1,5-dicafeoylquinic acid 144.2±11.0 Amentoflavones 147.7±15.8

From the results shown in Table 2 above, 1,3-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, and amentoflavone of the present invention show high collagen synthesis ability like the positive control TGF-beta. I could confirm.

Therefore, it can be seen that the 1,3-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, and amentoflavones of the present invention can reduce enlarged pores by increasing the amount of collagen produced around the pores.

[Test Example 4] Evaluation of skin pore contraction effect

The pore-reducing effect of 1,3-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, and amentoflavone was measured in comparison with tocopherol and EGCG. Divide 60 rhino mice into 6 groups of 10 mice each, and a 1% solution of 1,3-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid and amentoflavone, tocopherol or EGCG in each group of rhino mice (As a solvent, 1,3-butylene glycol:ethanol=7:3 was used) was applied by 0.5 ml each. At this time, only 0.5 ml of the solvent was applied to one group for comparison. The material was treated for 1 week and the dorsal portion was biopsied 24 hours after the last treatment. The epidermis was separated, immersed in 0.5% acetic acid, fixed in 10% formalin, and cut vertically into 6 mm. After staining with hematoxylin and eosin, the size of the pores was measured using a mechanical eyepiece micrometer. The results are shown in Table 3 below.

matter Pore size(mm) Control 65 Tocopherol 64 EGCG 60 1,3-dicafeoylquinic acid 53 1,5-dicafeoylquinic acid 54 Amentoflavones 50

As shown in Table 3, 1,3-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, and amentoflavone of the present invention have excellent effect of reducing the size of pores compared to tocopherol and EGCG. Can be seen.

[Reference Example] Preparation of Examples and Comparative Examples

According to the composition shown in Table 4 below, Examples 1 to 3 and Comparative Example 1 of a soft lotion (skin lotion) formulation were prepared by a conventional manufacturing method (unit:% by weight).

Ingredients Example 1 Example 2 Example 3 Comparative Example 1 Purified water Balance Balance Balance Balance 1,3-dicafeoylquinic acid 0.1 - - - 1,5-dicafeoylquinic acid - 0.1 - - Amentoflavones - - 0.1 - Butylene glycol 2.0 2.0 2.0 2.0 Propylene glycol 2.0 2.0 2.0 2.0 Carboxyvinyl polymer 0.1 0.1 0.1 0.1 PEG-12 nonylphenyl ether 0.2 0.2 0.2 0.2 Polysorbate 80 0.4 0.4 0.4 0.4 ethanol 10.0 10.0 10.0 10.0 Triethanolamine 0.1 0.1 0.1 0.1 Preservatives, colors, fragrance Appropriate amount Appropriate amount Appropriate amount Appropriate amount

[Test Example 5] Sensory evaluation for pore shrinkage

As the test subjects, 60 women aged 20-50 years old who had oily skin were randomly divided into 4 groups of 15 people each. For each group, after a certain period of time after washing, the products of Examples 1 to 3 or Comparative Example 1 were respectively applied, and the pore size was visually determined after 4 weeks after being performed twice a day in the morning and evening. It was measured. The results are shown in Table 5 below (evaluation grade: 0. Not reduced at all; 5. Very reduced)

division Evaluation grade Example 1 3.3 Example 2 3.2 Example 3 3.7 Comparative Example 1 0.8

As can be seen from the results of Table 5, the composition containing 1,3-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, and amentoflavone of the present invention does not contain any pore shrinking effect. There were significantly more users who answered that it was superior to the composition of the comparative example.

Therefore, it was found that the pore-constricting effect of the composition for external application for skin containing 1,3-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, and amentoflavone of the present invention was excellent.

Hereinafter, an example of the formulation of the composition according to the present invention will be described, but the pharmaceutical composition and the cosmetic composition can be applied in various formulations, and this is not intended to limit the present invention, but is intended to be described in detail.

[Formulation Example 1] Lotion

To prepare a lotion according to a conventional method with the composition shown in Table 6 below.

Content (% by weight) At least one compound selected from the group consisting of 1,3-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, and amentoflavones 2.0 glycerin 3.0 Butylene glycol 2.0 Propylene glycol 2.0 Carboxyvinyl polymer 0.1 PEG 12 nonylphenyl ether 0.2 Polysorbate 80 0.4 ethanol 10.0 Triethanolamine 0.1 Preservatives, colors, fragrance Appropriate amount Purified water Balance

[Formulation Example 2] Nourishing Cream

To prepare a nourishing cream according to a conventional method with the composition shown in Table 7 below.

Content (% by weight) At least one compound selected from the group consisting of 1,3-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, and amentoflavones 2.0 Polysorbate 60 1.5 Solbitansesuquioleate 0.5 PEG 60 hydrogenated castor oil 2.0 Floating paraffin 10.0 Squalane 5.0 Caprylic/Capractriglyceride 5.0 glycerin 5.0 Butylene glycol 3.0 Propylene glycol 3.0 Triethanolamine 0.2 Preservatives, colors, fragrance Appropriate amount Purified water Balance

[Formulation Example 3] Massage Cream

To prepare a massage cream according to a conventional method with the composition shown in Table 8 below.

Content (% by weight) At least one compound selected from the group consisting of 1,3-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, and amentoflavones 1.0 Beeswax 10.0 Polysorbate 60 1.5 PEG 60 hydrogenated castor oil 2.0 Sorbitansquioleate 0.8 Floating paraffin 40.0 Squalane 5.0 Caprylic/Capric Triglyceride 4.0 glycerin 5.0 Butylene glycol 3.0 Propylene glycol 3.0 Triethanolamine 0.2 Preservatives, colors, fragrance Appropriate amount Purified water Balance

[Formulation Example 4] Pack

To prepare a pack according to a conventional method with the composition shown in Table 9 below.

Content (% by weight) At least one compound selected from the group consisting of 1,3-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, and amentoflavones 1.0 Polyvinyl alcohol 13.0 Sodium carboxymethyl cellulose 0.2 glycerin 5.0 Allantoin 0.1 ethanol 6.0 PEG 12 nonylphenyl ether 0.3 Polysorbate 60 0.3 Preservatives, colors, fragrance Appropriate amount Purified water Balance

[Formulation Example 5] Gel

To prepare a gel according to a conventional method with the composition shown in Table 10 below.

Content (% by weight) At least one compound selected from the group consisting of 1,3-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, and amentoflavones 0.5 Sodium ethylenediamine acetate 0.05 glycerin 5.0 Carboxyvinyl polymer 0.3 ethanol 5.0 PEG 60 hydrogenated castor oil 0.5 Triethanolamine 0.3 Preservatives, colors, fragrance Appropriate amount Purified water Balance

[Formulation Example 6] Ointment

An ointment was prepared by a conventional method with the composition shown in Table 11 below.

Content (% by weight) At least one compound selected from the group consisting of 1,3-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, and amentoflavones 0.1 glycerin 8.0 Butylene glycol 4.0 Floating paraffin 15.0 Beta Glucan 7.0 Carbomer 0.1 Caprylic/Capric Triglyceride 3.0 Squalane 1.0 Cetearyl glucoside 1.5 Sorbitan stearate 0.4 Cetearyl alcohol 1.0 Beeswax 4.0 Preservatives, colors, fragrance Appropriate amount Purified water Balance

[Formulation Example 7] Soft Capsule

0.0025g of one or more compounds selected from the group consisting of 1,3-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid and amentoflavones, vitamin C 0.0025g, palm oil 2mg, hydrogenated palm oil 8mg, sulfur wax 4mg and 6 mg of lecithin was mixed, and 400 mg per capsule was filled according to a conventional method to prepare a soft capsule.

[Formulation Example 8] Tablet

0.0025g of one or more compounds selected from the group consisting of 1,3-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid and amentoflavones, vitamin C 0.0025g, glucose 100mg, starch 96mg and magnesium stearate 4mg After mixing and adding 40 mg of 30% ethanol to form granules, dried at 60° C. and tableted into tablets using a tablet press.

[Formulation Example 9] Granules

150 mg of one or more compounds selected from the group consisting of 1,3-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, and amentoflavones, 150 mg of vitamin C, 100 mg of glucose, and 600 mg of starch were mixed and 30% ethanol 100 mg of was added to form granules, and then dried at 60° C. to form granules, and then filled into a cloth. The final weight of the contents was 1 g.

[Formulation Example 10] Drink agent

0.0025 g of one or more compounds selected from the group consisting of 1,3-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid and amentoflavone, vitamin C 0.0025g, glucose 10g, citric acid 2g and purified water 187.8g Mixed and filled into bottles. The final volume of the contents was 200 ml.

As described above, specific parts of the present invention have been described in detail, and it is obvious that these specific techniques are only preferred embodiments for those of ordinary skill in the art, and the scope of the present invention is not limited thereby. something to do. Accordingly, it will be said that the substantial scope of the present invention is defined by the appended claims and their equivalents.

Claims (10)

As a cosmetic composition for shrinking pores comprising a substance that increases the expression of ABH antigen as an active ingredient,
Substances that increase the expression of the ABH antigen include 1,3-dicafeoylquinic acid, 1,5-dicafeoylquinic acid, and amentoflavone ( amentoflavone), characterized in that at least one compound selected from the group consisting of, a derivative thereof, or a salt thereof, a cosmetic composition for shrinking pores. The cosmetic composition of claim 1, wherein the composition contains a substance that increases the expression of the ABH antigen in an amount of 0.001% to 20% by weight based on the total weight of the composition. The cosmetic composition of claim 1, wherein the composition has an antioxidant activity and an activity of promoting collagen synthesis. A cosmetic composition for preventing pore expansion comprising a substance that increases the expression of ABH antigen as an active ingredient,
Substances that increase the expression of the ABH antigen include 1,3-dicafeoylquinic acid, 1,5-dicafeoylquinic acid, and amentoflavone ( amentoflavone), characterized in that at least one compound selected from the group consisting of, a derivative thereof, or a salt thereof, a cosmetic composition for preventing pore enlargement. The cosmetic composition of claim 4, wherein the composition contains a substance that increases the expression of the ABH antigen in an amount of 0.001% to 20% by weight based on the total weight of the composition. [6] The cosmetic composition of claim 4, wherein the composition has an antioxidant activity and an activity of promoting collagen synthesis. 1) checking the ABH antigen expression level of the test skin cell;
2) treating the test skin cells with a candidate substance;
3) checking the ABH antigen expression level of the test skin cells treated with the candidate substance; And
4) comparing the confirmation results of steps 1) and 3), and if the candidate substance is a substance that increases the expression of the ABH antigen, determining a substance having pore-reduction or pore-enlargement inhibitory activity;
A method for screening a substance having an activity of reducing pores or inhibiting pore expansion, comprising a. The method of claim 7,
The step 1) further comprises the step of checking the collagen synthesis level of the test skin cells and the skin pore size of the test animal (except for humans),
The step 2) further comprises applying the candidate material to the skin of the test animal,
The step 3) further comprises confirming the collagen synthesis level of the test skin cells treated with the candidate substance and the skin pore size of the test animal to which the candidate substance was applied,
Step 4) compares the ABH antigen expression level and collagen synthesis level of the test skin cells before and after the candidate substance treatment, and the result of confirming the skin pore size of the test animal before and after application of the candidate substance, and the candidate substance is the ABH antigen. If it is a substance that increases the expression of, promotes collagen synthesis, and shrinks skin pores, it is determined as a substance having pore shrinking or pore expansion inhibiting activity. Way. The method of claim 8, wherein the method further comprises the step of confirming the antioxidant activity of the candidate substance, wherein the candidate substance increases the expression of ABH antigen, promotes collagen synthesis, has antioxidant activity, and contracts skin pores. A method for screening a substance having pore-reduction or pore-enlargement inhibitory activity, characterized in that it is determined as a substance having pore-reduction or pore-enlargement inhibitory activity if it is a material to be used. The method of claim 7, wherein the substance that increases the expression of the ABH antigen is 1,3-dicafeoylquinic acid, 1,5-dicafeoylquinic acid. ) And amentoflavone (amentoflavone), characterized in that at least one compound selected from the group consisting of, a derivative thereof, or a pharmaceutically acceptable salt thereof.

Images